NEW YORK — GenomeSmart said on Tuesday that specialty medical technology firm Aspira Labs will evaluate its GenomeBrain digital genetic test recommendation platform under a pilot program.
GenomeBrain uses artificial intelligence to match a person's personal and medical history, as well as ethnicity and age, with national guidelines to recommended medically actionable genetic tests. The platform then generates a report that clinicians and their patients can use to determine a testing plan, according to Los Altos, California-based GenomeSmart.
Aspira, a subsidiary of Austin, Texas-based Vermillion, will offer GenomeBrain to a select group of its customers to improve identification of patients who are at risk for hereditary cancer or passing hereditary diseases to their children. Participating healthcare providers will incorporate the platform into their current patient workflows to evaluate its effectiveness and ease of use.
Additional terms of the deal were not disclosed.
"We're pleased to have Aspira Labs as our first pilot with a genetic testing lab," GenomeSmart Cofounder and CEO Sanjay Sathe said in a statement. "We look forward to using the information from this program to continue our commercialization and future development."
The deal follows a similar agreement last month when GenomeSmart signed on Northern California healthcare system NorthBay Healthcare to try out GenomeBrain in its breast cancer patient workflows.